EcoDrugPlus

Coagulation Factor Ii (Thrombin) Receptor

Ensembl ID : ENSCCRG00000019984
Gene Symbol: F2R
1 Cross references
208 Possible Orthologues:

Coagulation Factor Ii (Thrombin) Receptor

Ensembl ID : ENSCCRG00000025914
Gene Symbol: F2R
1 Cross references
208 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSCCRG00000059546
Gene Symbol: F2R
1 Cross references
240 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSCCRG00000077171
Gene Symbol: F2R
1 Cross references
240 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSCCRG00000037167
Gene Symbol: F2R
1 Cross references
242 Possible Orthologues:

Coagulation Factor Iii, Tissue Factor

Ensembl ID : ENSCCRG00000023253
Gene Symbol: F3
1 Cross references
169 Possible Orthologues:

Coagulation Factor Iiia

Ensembl ID : ENSCCRG00000050185
Gene Symbol: F3A
1 Cross references
196 Possible Orthologues:

Coagulation Factor Iiia

Ensembl ID : ENSCCRG00000033912
Gene Symbol: F3A
1 Cross references
194 Possible Orthologues:

Coagulation Factor Vii, Like

Ensembl ID : ENSCCRG00000077146
Gene Symbol: F7L
1 Cross references
202 Possible Orthologues:

Coagulation Factor X

Ensembl ID : ENSCCRG00000052475
Gene Symbol: F10
1 Cross references
243 Possible Orthologues:

Coagulation Factor X

Ensembl ID : ENSCCRG00000059290
Gene Symbol: F10
1 Cross references
243 Possible Orthologues:

Coiled-Coil Domain Containing 6a

Ensembl ID : ENSCCRG00000031256
Gene Symbol: CCDC6A
1 Cross references
205 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).